How ‘diabesity drugs’ could change the investment landscape episode artwork

EPISODE · Apr 24, 2024 · 9 MIN

How ‘diabesity drugs’ could change the investment landscape

from In the market for more · host IG Group

Trial results from Eli Lilly add to a growing body of evidence that suggests GLP-1 drugs, which include treatments like Lilly’s Mounjaro and Novo Nordisk’s Wegovy have medical benefits beyond diabetes and weight loss. Tematica CIO Chris Versace explains how these so-called ‘diabesity drugs‘ could affect healthcare and why their impact, positive and negative, could not be known for some time. He also discusses the impact of oil prices on monetary policy and Netflix.Any opinion, news, research, analysis, or other information does not constitute investment or trading advice. Follow us on Twitter, Instagram, and YouTube *Your capital is at risk. 71% of retail CFD accounts lose money*

NOW PLAYING

How ‘diabesity drugs’ could change the investment landscape

0:00 9:27

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of In the market for more?

This episode is 9 minutes long.

When was this In the market for more episode published?

This episode was published on April 24, 2024.

What is this episode about?

Trial results from Eli Lilly add to a growing body of evidence that suggests GLP-1 drugs, which include treatments like Lilly’s Mounjaro and Novo Nordisk’s Wegovy have medical benefits beyond diabetes and weight loss. Tematica CIO Chris Versace...

Can I download this In the market for more episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!